Ekso Bionics Q4 2024 Earnings Report
Key Takeaways
Ekso Bionics reported a record Q4 revenue of $5.1 million, a 5% increase compared to the same period in 2023. The company's gross profit increased by 15% to $2.7 million, with a gross margin of approximately 53%. Net loss for the quarter was $3.4 million, or $0.14 per share.
Record Q4-2024 revenue of $5.1 million
Gross profit increased 15% compared to Q4 2023
Gross margin improved to approximately 53%
National Seating & Mobility named exclusive Ekso Indego® Personal device distributor
Ekso Bionics
Ekso Bionics
Forward Guidance
The Company's focus will be on aggressively executing two key pillars of its growth strategy: (1) broadening patient access to Ekso Indego® Personal and building upon our growing CMS claim pipeline for the device; and (2), further bolstering demand for our legacy EksoNR device.